Search results
AstraZeneca's Fasenra Flunks Late-Stage Trial In Patients With Esophagus Inflammation
Benzinga via Yahoo Finance· 2 years agoAstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra...
AstraZeneca Plc (NASDAQ: AZN) has reported topline data from the MESSINA Phase 3 trial Fasenra...